Tag: Zynerba

StaffNovember 14, 2017
shutterstock_578810947.jpg
BusinessPublic

Zynerba Losses Rise As Company Pushes Forward On Fragile-X

4min00
Pennsylvania-based Zynerba Pharmaceuticals, Inc. (ZYNE),  reported its third-quarter earnings for the period ending September 30, 2017. The biotech company delivered a net loss of $8.3 million with basic and diluted net loss per share of $0.63. This is greater than last year’s loss of $5.9 million. The company has no revenues to report yet as the […]
CONTINUE READING
Debra BorchardtSeptember 29, 2017
growingfacility-1280x856.jpg
Banking

Zynerba Pops, While GW Pharmaceuticals Drops

3min00
Zynerba (ZYNE)  stock jumped 53% on news that its results from a Phase 2 clinical trial for lead candidate ZYN002 with Fragile-X patients had positive results. The 20-subject study showed a 46% improvement from the baseline and had meaningful improvements in key behavioral characteristics. However, Alfredo Fontanini pointed out on Twitter @AF_biotech that when you […]
CONTINUE READING

Newer Posts

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis

READ MORE
Recent Tweets
Company

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.